Cresset Expands Sales Pipeline Potential through CambridgeSoft Alliance
News Apr 20, 2009
Cresset Biomolecular Discovery Ltd (Cresset), announces that their recent distribution agreement with CambridgeSoft© Corporation has led to an increase in the company’s sales pipeline.
Under the terms of the agreement, CambridgeSoft sells Cresset’s FieldAlign and FieldTemplater products using its direct, telesales and ecommerce channels. FieldAlign and FieldTemplater are designed for both molecular modellers and medicinal chemists who want to discover new drugs against a wide range of biological targets. The products enable scientists to determine important interactions between ligands and proteins and to efficiently prioritize compounds for biological evaluation.
“I believe that this partnership will enable Cresset to increase sales of FieldAlign and FieldTemplater this year. The interest that Cambridgesoft has generated in our products is very encouraging, and I look forward to more organisations using these tools to develop new medicines” said Bea Leigh, CEO, Cresset BioMolecular Discovery.
“We are excited to be able to provide Cresset’s innovative solutions to our established customer base,” said Michael G. Tomasic, President and Chief Executive Officer of CambridgeSoft. “By delivering FieldAlign and FieldTemplater to CambridgeSoft customers through established business channels, we will extend the reach of these valuable tools to a wider audience of scientists, and help them apply field technology to hit-finding, lead-switching, IP scanning, and portfolio management.”
Cresset is leveraging CambridgeSoft’s established sales and marketing infrastructure to enable their inspiring products to reach a larger chemistry market. The initial CambridgeSoft campaigns promoting Cresset’s free one month evaluation of FieldAlign and FieldTemplater software have been successful. Through a link in CambridgeSoft’s online Scistore.com, Cresset has seen the number of trial downloads increase 10 fold over the previous quarter swelling their sales pipeline.
Researchers say they have discovered a gene mutation that slows the metabolism of sugar in the gut, giving people who have the mutation a lower risk of diabetes, obesity, heart failure, and even death. The researchers say their finding could provide the basis for drug therapies that could mimic the workings of this gene mutation.
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019
2nd International Conference on Computational Biology and Bioinformatics
May 17 - May 18, 2019